2015 American Transplant Congress
Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation
Introduction:Sofosbuvir is approved to treat HCV infection in all genotypes with sustained virological response 12 weeks after completion of therapy (SVR12)rates of up to 100%.…2015 American Transplant Congress
End of Treatment Liver Biopsy With Sofosbuvir: Histologic Changes Suggestive of Hepatitis C Activity in Liver Transplant Recipients With Achieved SVR
Background: Interferon (IFN) free HCV regimens are associated with better tolerability and efficacy. The majority of studies report biochemical and virological response; however limited information…2015 American Transplant Congress
Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience
Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…2015 American Transplant Congress
Preventing Cytomegalovirus Infection in Intermediate-High Risk Liver Transplant Recipients: Acyclovir Vs Valganciclovir
Department of Pharmacy, New York Presbyterian Hospital, New York City, NY.
Cytomegalovirus (CMV) is an opportunistic infection responsible for profound morbidity and mortality among solid organ transplant recipients. A donor and recipient's CMV IgG serostatus influences…2015 American Transplant Congress
CMV prevalence in Mauritian and Indonesian Cynomolgus Macaques: Significance in Transplantation and CMV Disease Models
Despite the finding that most macaques express high serologic titers of anti-CMV antibody, susceptibility to disease appears to be variable post-transplant. This observation led us…2015 American Transplant Congress
African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
Houston Methodist Hospital, Houston, TX.
Safe and effective use of low-dose (450 mg/day) valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in renal transplant recipients (RTRs) has been reported. However, it is…2015 American Transplant Congress
The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disease (PTLD) in Solid Organ Transplant Recipients: A Systematic Review
Background The role of antiviral prophylaxis in EBV seronegative solid organ transplant recipients receiving organs from seropositive donors for prevention of PTLD remains controversial. We…2015 American Transplant Congress
Safety and Efficacy of Pegylated Interferon and Ribavirin for Chronic Hepatitis C Following Renal Transplantation
Objective We sought to investigate the safety and efficacy of pegylated Interferon (PEG-IFN) and ribavirin for chronic hepatitis C (HCV) following renal transplantation.Methods Ten adult…2015 American Transplant Congress
Incidence of CMV Viremia in Obese and Morbidly Obese Kidney Transplants Under a Low Dose Valganciclovir Prophylaxis Protocol
1Pharmacy Practice, Univ of IL-Chicago, Chicago, IL; 2Surgery, Univ of IL-Chicago, Chicago, IL.
Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to…2015 American Transplant Congress
Clinical and Virologic Outcomes in High-Risk Adult EBV D+/R- Organ Transplant Recipients
Background:EBV D+/R- organ transplant recipients are a high risk group for developing PTLD. This subgroup of patients has been primarily evaluated in pediatric populations with…
American Transplant Congress abstracts